NCT05297578Phase 2Completed

Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Older Adults

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2023-02-15Actual

Enrollment · participants207Actual

Source updated2024-10-09Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Pneumococcal Vaccines

Treatments or interventions studied

24-Valent Pneumococcal Conjugate VaccineBiological
Pneumococcal 20-valent Conjugate VaccineBiologicalAlso known as Prevnar 20, PCV20

Primary outcomes · main study measures

Read the study measures

measure: Percentage of Participants Reporting Solicited Local Reactions Within 7 Days After Vaccination; description: Solicited local reactions included redness/erythema, swelling/induration, and pain at injection site; timeFrame: 7 days after vaccination; measure: Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination; description: Solicited systemic reactions include fever, headache, fatigue, muscle pain, and joint pain within 7 days of vaccination; timeFrame: 7 days after vaccination; measure: Percentage of Subjects Reporting Unsolicited Adverse Events Within 1 Month After Vaccination; description: Percentage of participants with at least one Treatment Emergent Adverse Event (unsolicited AEs and SAEs); timeFrame: 1 month after vaccination; measure: Percentage of Participants Reporting SAEs and New Onset of Chronic Illnesses (NOCIs); description: Percentage of participants with serious adverse events (SAEs) and new onset of chronic illness (NOCIs); timeFrame: 6 months after vaccination

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history